Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 ...

The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard ...

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...

Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor/tezacaftor/ivacaftor) for the ...

Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Continued FDA approval of iptacopan was contingent on 2-year trial data ...

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of ...

WASHINGTON, D.C. (7News) — Monday is shaping up to be a high impact weather day not just for the DMV, but for a large stretch of the Mid-Atlantic and East Coast. 7News First Alert Weather Team has ...

What Is It, and Why Does It Matter? Icotyde (icotrokinra) is a once-daily pill for moderate to severe plaque psoriasis. It is for adults and for those 12 years and older who weigh at least 40 ...

A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...